Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | CPA2 | P48052 | 1/20 | 0.42 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 5/20 | 0.40 |
| ▸ | CCKBR | P32239 | 5/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14129704 | 0.85 | SSTR3 (0.48) | CPA1CPA2CPA4SSTR3CCKAR | |
| SCHEMBL26015579 | 0.84 | ITGB1 (0.43) | FOLH1 | |
| SCHEMBL31681443 | 0.83 | SIRT1 (0.37) | CPA1CPA2CPA4SIRT2SIRT1 | |
| SCHEMBL15928006 | 0.81 | SSTR3 (0.44) | SSTR3SIRT2SIRT1 | |
| SCHEMBL25242024 | 0.81 | FOLH1 (0.37) | SIRT2SIRT1FOLH1 | |
| SCHEMBL25242026 | 0.81 | FOLH1 (0.37) | SIRT2SIRT1FOLH1 | |
| SCHEMBL26024621 | 0.81 | FOLH1 (0.41) | FOLH1 | |
| SCHEMBL19732156 | 0.80 | FOLH1 (0.37) | SIRT2SIRT1FOLH1 | |
| SCHEMBL22618772 | 0.79 | FURIN (0.40) | SIRT2SIRT1 | |
| SCHEMBL22618827 | 0.79 | C3AR1 (0.41) | SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067006-B2 | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites | IMMUNOMEDICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100233779-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | IMMUNOMEDICS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171067-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | CPA1 1468/4885CPA2 1743/4885CPA4 1762/4885 |
| US-20100233779-A1 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites | CD47, BSG, SELPLG | CPA1 1468/4885CPA2 1743/4885CPA4 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.